The following table provides the components of inventories:

Raw materials includes plasma and other materials expected to be used in the production of ASCENIV and BIVIGAM, as there are alternative uses for these materials that provide a probable future benefit or will be consumed in the production of goods expected to be available for sale. All other activities and materials associated with the production of inventories used in research and development activities are expensed as incurred.

Work-in-process inventory at June 30, 2019 consists of $2.1 million of ASCENIV, $1.0 million of BIVIGAM and $1.5 million of Nabi-HB. Finished goods inventory at June 30, 2019 is comprised of $1.5 million of Nabi-HB, $0.9 million of product manufactured under a contract manufacturing agreement, $0.4 million of plasma collected at the Company’s plasma collection center and $0.2 million of intermediates. Finished goods inventory at December 31, 2018 is comprised of $2.3 million of Nabi-HB, $1.2 million of product manufactured under a contract manufacturing agreement and $1.1 million of plasma collected at the Company’s plasma collection centers.